Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma

What is this summary about? This plain language summary describes the results of the first study on subcutaneous (under the skin) injection of a medicine called isatuximab for people with multiple myeloma. Multiple myeloma is a type of blood cancer. Isatuximab is approved in various countries, to be...

Descripción completa

Detalles Bibliográficos
Autores: Quach, Hang, Parmar, Gurdeep, Ocio San Miguel, Enrique María|||0000-0002-5765-0085, Prince, Miles, Oriol, Albert, Tsukada, Nobuhiro, Bories, Pierre, Yu, Disa, Suzan, Florence, Moreau, Philippe
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/38814
Acceso en línea:https://hdl.handle.net/10902/38814
Access Level:acceso abierto
id ES_12814d1da25aca415744792df4f96ef6
oai_identifier_str oai:repositorio.unican.es:10902/38814
network_acronym_str ES
network_name_str España
repository_id_str
spelling Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myelomaQuach, HangParmar, GurdeepOcio San Miguel, Enrique María|||0000-0002-5765-0085Prince, MilesOriol, AlbertTsukada, NobuhiroBories, PierreYu, DisaSuzan, FlorenceMoreau, PhilippeWhat is this summary about? This plain language summary describes the results of the first study on subcutaneous (under the skin) injection of a medicine called isatuximab for people with multiple myeloma. Multiple myeloma is a type of blood cancer. Isatuximab is approved in various countries, to be given as an intravenous infusion (into a vein) alongside other medicines for people with multiple myeloma. Subcutaneous injection would reduce the time needed for the injection to take place and decrease the need for nurses to be involved. Isatuximab was given to some people with multiple myeloma as a subcutaneous injection, using a new type of injector called an on-body delivery system (OBDS for short). Other people with multiple myeloma received isatuximab intravenously. This would allow for researchers to compare the results. Everyone in the study also received treatment with pomalidomide and low-dose dexamethasone. What were the results? The results of the study showed that isatuximab could be given as a subcutaneous injection using an OBDS. The side effects that people experienced were similar to those in people who received isatuximab as an infusion in the study described, as well as in the larger study called ICARIA-MM. People with multiple myeloma receiving subcutaneous isatuximab with an OBDS did not have any infusion/injection reaction. Side effects around the site of the injection were categorized as mild and infrequent. The OBDS injection took 10 minutes or less to complete for half of the people in the study. Multiple myeloma improved for 73% of people who received isatuximab as a subcutaneous OBDS injection. This was similar to people who received isatuximab as an intravenous infusion ? 67% of people?s multiple myeloma improved in this group. What do the results mean? In this study, subcutaneous injection of isatuximab using an OBDS worked as well as intravenous infusion, with similar side effects. Receiving isatuximab as a subcutaneous injection could be a more convenient treatment option for people with multiple myeloma.[Box: see text].Taylor & FrancisUniversidad de Cantabria20252025-01-01journal articlehttp://purl.org/coar/resource_type/c_6501NAhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43info:eu-repo/semantics/articlehttps://hdl.handle.net/10902/38814Future Oncology, 2025, 21(19), 2415-2428reponame:UCrea Repositorio Abierto de la Universidad de Cantabriainstname:Universidad de Cantabria (UC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:repositorio.unican.es:10902/388142026-06-02T12:39:31Z
dc.title.none.fl_str_mv Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma
title Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma
spellingShingle Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma
Quach, Hang
title_short Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma
title_full Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma
title_fullStr Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma
title_full_unstemmed Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma
title_sort Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma
dc.creator.none.fl_str_mv Quach, Hang
Parmar, Gurdeep
Ocio San Miguel, Enrique María|||0000-0002-5765-0085
Prince, Miles
Oriol, Albert
Tsukada, Nobuhiro
Bories, Pierre
Yu, Disa
Suzan, Florence
Moreau, Philippe
author Quach, Hang
author_facet Quach, Hang
Parmar, Gurdeep
Ocio San Miguel, Enrique María|||0000-0002-5765-0085
Prince, Miles
Oriol, Albert
Tsukada, Nobuhiro
Bories, Pierre
Yu, Disa
Suzan, Florence
Moreau, Philippe
author_role author
author2 Parmar, Gurdeep
Ocio San Miguel, Enrique María|||0000-0002-5765-0085
Prince, Miles
Oriol, Albert
Tsukada, Nobuhiro
Bories, Pierre
Yu, Disa
Suzan, Florence
Moreau, Philippe
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad de Cantabria
description What is this summary about? This plain language summary describes the results of the first study on subcutaneous (under the skin) injection of a medicine called isatuximab for people with multiple myeloma. Multiple myeloma is a type of blood cancer. Isatuximab is approved in various countries, to be given as an intravenous infusion (into a vein) alongside other medicines for people with multiple myeloma. Subcutaneous injection would reduce the time needed for the injection to take place and decrease the need for nurses to be involved. Isatuximab was given to some people with multiple myeloma as a subcutaneous injection, using a new type of injector called an on-body delivery system (OBDS for short). Other people with multiple myeloma received isatuximab intravenously. This would allow for researchers to compare the results. Everyone in the study also received treatment with pomalidomide and low-dose dexamethasone. What were the results? The results of the study showed that isatuximab could be given as a subcutaneous injection using an OBDS. The side effects that people experienced were similar to those in people who received isatuximab as an infusion in the study described, as well as in the larger study called ICARIA-MM. People with multiple myeloma receiving subcutaneous isatuximab with an OBDS did not have any infusion/injection reaction. Side effects around the site of the injection were categorized as mild and infrequent. The OBDS injection took 10 minutes or less to complete for half of the people in the study. Multiple myeloma improved for 73% of people who received isatuximab as a subcutaneous OBDS injection. This was similar to people who received isatuximab as an intravenous infusion ? 67% of people?s multiple myeloma improved in this group. What do the results mean? In this study, subcutaneous injection of isatuximab using an OBDS worked as well as intravenous infusion, with similar side effects. Receiving isatuximab as a subcutaneous injection could be a more convenient treatment option for people with multiple myeloma.[Box: see text].
publishDate 2025
dc.date.none.fl_str_mv 2025
2025-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
NA
http://purl.org/coar/version/c_be7fb7dd8ff6fe43
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10902/38814
url https://hdl.handle.net/10902/38814
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv Future Oncology, 2025, 21(19), 2415-2428
reponame:UCrea Repositorio Abierto de la Universidad de Cantabria
instname:Universidad de Cantabria (UC)
instname_str Universidad de Cantabria (UC)
reponame_str UCrea Repositorio Abierto de la Universidad de Cantabria
collection UCrea Repositorio Abierto de la Universidad de Cantabria
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403622382501888
score 15,812429

Similares en LA Referencia